Biomimetic nanoparticle technology for cardiovascular disease detection and treatment
Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately l...
Gespeichert in:
Veröffentlicht in: | Nanoscale horizons 2020-01, Vol.5 (1), p.25-42 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 42 |
---|---|
container_issue | 1 |
container_start_page | 25 |
container_title | Nanoscale horizons |
container_volume | 5 |
creator | Park, Joon Ho Dehaini, Diana Zhou, Jiarong Holay, Maya Fang, Ronnie H Zhang, Liangfang |
description | Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately lead to traumatic events such as a heart attack or stroke. While the knowledge obtained in the past century regarding the cardiovascular system has paved the way for the development of life-prolonging drugs and treatment modalities, CVD remains one of the leading causes of death in developed countries. More recently, researchers have explored the application of nanotechnology to improve upon current clinical paradigms for the management of CVD. Nanoscale delivery systems have many advantages, including the ability to target diseased sites, improve drug bioavailability, and carry various functional payloads. In this review, we cover the different ways in which nanoparticle technology can be applied towards CVD diagnostics and treatments. The development of novel biomimetic platforms with enhanced functionalities is discussed in detail.
Biomimetic nanoparticle technology has the potential to significantly improve the clinical management of cardiovascular disease. |
doi_str_mv | 10.1039/c9nh00291j |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1039_C9NH00291J</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2326857415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-f236656b4b048ace81be68bfba23f5178b20dd52c0c899fad5769ed2ccf7d7e83</originalsourceid><addsrcrecordid>eNpVkUtLAzEUhYMotmg37pUBd0I1j0km2QhafCK60XXIJBmbMpPUZFrovzfaWnV1L9yPcw73AHCE4DmCRFxo4acQYoFmO2CIIaVjVrFyd7tTNgCjlGYQQsRRJTjZBwOCESGIwiF4u3ahc53tnS688mGuYl5bW_RWT31ow_uqaEIstIrGhaVKetGqWBiXrEq2MDZzvQu-UN4UfbSq76zvD8Feo9pkR5t5AN5ub14n9-Onl7uHydXTWJdM9OMGE8Yoq8sallxpy1FtGa-bWmHSUFTxGkNjKNZQcyEaZWjFhDVY66YyleXkAFyudeeLurNGZ-uoWjmPrlNxJYNy8v_Fu6l8D0tZ5eeUgmSB041ADB8Lm3o5C4voc2aJCWacViWimTpbUzqGlKJttg4Iyq8W5EQ833-38Jjhk7-ZtujPzzNwvAZi0tvrb43kE7LJjyU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2326857415</pqid></control><display><type>article</type><title>Biomimetic nanoparticle technology for cardiovascular disease detection and treatment</title><source>MEDLINE</source><source>Royal Society Of Chemistry Journals 2008-</source><creator>Park, Joon Ho ; Dehaini, Diana ; Zhou, Jiarong ; Holay, Maya ; Fang, Ronnie H ; Zhang, Liangfang</creator><creatorcontrib>Park, Joon Ho ; Dehaini, Diana ; Zhou, Jiarong ; Holay, Maya ; Fang, Ronnie H ; Zhang, Liangfang</creatorcontrib><description>Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately lead to traumatic events such as a heart attack or stroke. While the knowledge obtained in the past century regarding the cardiovascular system has paved the way for the development of life-prolonging drugs and treatment modalities, CVD remains one of the leading causes of death in developed countries. More recently, researchers have explored the application of nanotechnology to improve upon current clinical paradigms for the management of CVD. Nanoscale delivery systems have many advantages, including the ability to target diseased sites, improve drug bioavailability, and carry various functional payloads. In this review, we cover the different ways in which nanoparticle technology can be applied towards CVD diagnostics and treatments. The development of novel biomimetic platforms with enhanced functionalities is discussed in detail.
Biomimetic nanoparticle technology has the potential to significantly improve the clinical management of cardiovascular disease.</description><identifier>ISSN: 2055-6756</identifier><identifier>ISSN: 2055-6764</identifier><identifier>EISSN: 2055-6764</identifier><identifier>DOI: 10.1039/c9nh00291j</identifier><identifier>PMID: 32133150</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Bioavailability ; Biomimetics ; Biomimetics - methods ; Blood vessels ; Cardiovascular disease ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - therapy ; Heart diseases ; Humans ; Nanoparticles ; Nanoparticles - therapeutic use ; Nanotechnology ; Nanotechnology - methods ; Payloads</subject><ispartof>Nanoscale horizons, 2020-01, Vol.5 (1), p.25-42</ispartof><rights>Copyright Royal Society of Chemistry 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-f236656b4b048ace81be68bfba23f5178b20dd52c0c899fad5769ed2ccf7d7e83</citedby><cites>FETCH-LOGICAL-c469t-f236656b4b048ace81be68bfba23f5178b20dd52c0c899fad5769ed2ccf7d7e83</cites><orcidid>0000-0003-0637-0654</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32133150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Joon Ho</creatorcontrib><creatorcontrib>Dehaini, Diana</creatorcontrib><creatorcontrib>Zhou, Jiarong</creatorcontrib><creatorcontrib>Holay, Maya</creatorcontrib><creatorcontrib>Fang, Ronnie H</creatorcontrib><creatorcontrib>Zhang, Liangfang</creatorcontrib><title>Biomimetic nanoparticle technology for cardiovascular disease detection and treatment</title><title>Nanoscale horizons</title><addtitle>Nanoscale Horiz</addtitle><description>Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately lead to traumatic events such as a heart attack or stroke. While the knowledge obtained in the past century regarding the cardiovascular system has paved the way for the development of life-prolonging drugs and treatment modalities, CVD remains one of the leading causes of death in developed countries. More recently, researchers have explored the application of nanotechnology to improve upon current clinical paradigms for the management of CVD. Nanoscale delivery systems have many advantages, including the ability to target diseased sites, improve drug bioavailability, and carry various functional payloads. In this review, we cover the different ways in which nanoparticle technology can be applied towards CVD diagnostics and treatments. The development of novel biomimetic platforms with enhanced functionalities is discussed in detail.
Biomimetic nanoparticle technology has the potential to significantly improve the clinical management of cardiovascular disease.</description><subject>Bioavailability</subject><subject>Biomimetics</subject><subject>Biomimetics - methods</subject><subject>Blood vessels</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - therapy</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Nanoparticles</subject><subject>Nanoparticles - therapeutic use</subject><subject>Nanotechnology</subject><subject>Nanotechnology - methods</subject><subject>Payloads</subject><issn>2055-6756</issn><issn>2055-6764</issn><issn>2055-6764</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtLAzEUhYMotmg37pUBd0I1j0km2QhafCK60XXIJBmbMpPUZFrovzfaWnV1L9yPcw73AHCE4DmCRFxo4acQYoFmO2CIIaVjVrFyd7tTNgCjlGYQQsRRJTjZBwOCESGIwiF4u3ahc53tnS688mGuYl5bW_RWT31ow_uqaEIstIrGhaVKetGqWBiXrEq2MDZzvQu-UN4UfbSq76zvD8Feo9pkR5t5AN5ub14n9-Onl7uHydXTWJdM9OMGE8Yoq8sallxpy1FtGa-bWmHSUFTxGkNjKNZQcyEaZWjFhDVY66YyleXkAFyudeeLurNGZ-uoWjmPrlNxJYNy8v_Fu6l8D0tZ5eeUgmSB041ADB8Lm3o5C4voc2aJCWacViWimTpbUzqGlKJttg4Iyq8W5EQ833-38Jjhk7-ZtujPzzNwvAZi0tvrb43kE7LJjyU</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Park, Joon Ho</creator><creator>Dehaini, Diana</creator><creator>Zhou, Jiarong</creator><creator>Holay, Maya</creator><creator>Fang, Ronnie H</creator><creator>Zhang, Liangfang</creator><general>Royal Society of Chemistry</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>7TB</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>FR3</scope><scope>JG9</scope><scope>L7M</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0637-0654</orcidid></search><sort><creationdate>20200101</creationdate><title>Biomimetic nanoparticle technology for cardiovascular disease detection and treatment</title><author>Park, Joon Ho ; Dehaini, Diana ; Zhou, Jiarong ; Holay, Maya ; Fang, Ronnie H ; Zhang, Liangfang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-f236656b4b048ace81be68bfba23f5178b20dd52c0c899fad5769ed2ccf7d7e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bioavailability</topic><topic>Biomimetics</topic><topic>Biomimetics - methods</topic><topic>Blood vessels</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - therapy</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Nanoparticles</topic><topic>Nanoparticles - therapeutic use</topic><topic>Nanotechnology</topic><topic>Nanotechnology - methods</topic><topic>Payloads</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Joon Ho</creatorcontrib><creatorcontrib>Dehaini, Diana</creatorcontrib><creatorcontrib>Zhou, Jiarong</creatorcontrib><creatorcontrib>Holay, Maya</creatorcontrib><creatorcontrib>Fang, Ronnie H</creatorcontrib><creatorcontrib>Zhang, Liangfang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Materials Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nanoscale horizons</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Joon Ho</au><au>Dehaini, Diana</au><au>Zhou, Jiarong</au><au>Holay, Maya</au><au>Fang, Ronnie H</au><au>Zhang, Liangfang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomimetic nanoparticle technology for cardiovascular disease detection and treatment</atitle><jtitle>Nanoscale horizons</jtitle><addtitle>Nanoscale Horiz</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>5</volume><issue>1</issue><spage>25</spage><epage>42</epage><pages>25-42</pages><issn>2055-6756</issn><issn>2055-6764</issn><eissn>2055-6764</eissn><abstract>Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately lead to traumatic events such as a heart attack or stroke. While the knowledge obtained in the past century regarding the cardiovascular system has paved the way for the development of life-prolonging drugs and treatment modalities, CVD remains one of the leading causes of death in developed countries. More recently, researchers have explored the application of nanotechnology to improve upon current clinical paradigms for the management of CVD. Nanoscale delivery systems have many advantages, including the ability to target diseased sites, improve drug bioavailability, and carry various functional payloads. In this review, we cover the different ways in which nanoparticle technology can be applied towards CVD diagnostics and treatments. The development of novel biomimetic platforms with enhanced functionalities is discussed in detail.
Biomimetic nanoparticle technology has the potential to significantly improve the clinical management of cardiovascular disease.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>32133150</pmid><doi>10.1039/c9nh00291j</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-0637-0654</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2055-6756 |
ispartof | Nanoscale horizons, 2020-01, Vol.5 (1), p.25-42 |
issn | 2055-6756 2055-6764 2055-6764 |
language | eng |
recordid | cdi_crossref_primary_10_1039_C9NH00291J |
source | MEDLINE; Royal Society Of Chemistry Journals 2008- |
subjects | Bioavailability Biomimetics Biomimetics - methods Blood vessels Cardiovascular disease Cardiovascular Diseases - diagnosis Cardiovascular Diseases - therapy Heart diseases Humans Nanoparticles Nanoparticles - therapeutic use Nanotechnology Nanotechnology - methods Payloads |
title | Biomimetic nanoparticle technology for cardiovascular disease detection and treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A49%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomimetic%20nanoparticle%20technology%20for%20cardiovascular%20disease%20detection%20and%20treatment&rft.jtitle=Nanoscale%20horizons&rft.au=Park,%20Joon%20Ho&rft.date=2020-01-01&rft.volume=5&rft.issue=1&rft.spage=25&rft.epage=42&rft.pages=25-42&rft.issn=2055-6756&rft.eissn=2055-6764&rft_id=info:doi/10.1039/c9nh00291j&rft_dat=%3Cproquest_cross%3E2326857415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2326857415&rft_id=info:pmid/32133150&rfr_iscdi=true |